TITLE

Dendreon: $356M Sale to Make Provenge, Gear Up for Launch

AUTHOR(S)
Hollingsworth, Catherine
PUB. DATE
December 2009
SOURCE
BioWorld Today;12/14/2009, Vol. 20 Issue 239, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the stock offering launched by Dendreon Corp. in an effort to raise approximately 356 million U.S. dollar. Dendreon priced its offering at 24.75 U.S. dollar per share of stock. The company plans to allocate proceeds from the stock offering to advanced the construction of its manufacturing facilities and prepare for the launch of its prostate cancer immunotherapy, Provenge. Information on Provenge is also provided.
ACCESSION #
47123497

 

Related Articles

  • Stock Movers.  // BioWorld Today;9/5/2012, Vol. 23 Issue 172, p2 

    A chart is presented that shows changes in the prices of several biotechnology stocks as of September 4, 2012, including Nasdaq Biotechnology, BioSante Pharmaceuticals Inc. and Dendreon Corp.

  • Dendreon Shares Surge, As Do Others In Cancer Immunotherapy. Lorenzo, Aaron // BioWorld Today;4/2/2007, Vol. 18 Issue 63, p1 

    The article presents updates on the performance of the stocks of several pharmaceutical companies in the U.S. for the week ending March 30, 2007. The Dendreon Corp. gained a 148 percent, or $7.71 increase, to close at $12.93. Meanwhile, Genesys Inc. gained 20 percent to close at $4.20. Favrille...

  • Prostate Cancer Update.  // PharmaWatch: Cancer;Aug2006, Vol. 5 Issue 8, p11 

    The article provides update related to prostate cancer. The shares of Dendreon Corp. were lifted by more than 10 percent after the company reported impressive phase III survival data for its cancer immunotherapy Provenge. Shares in Praecis Pharmaceuticals Inc. fell around 30 percent after the...

  • Biotechnology News Round-up.  // PharmaWatch: Monthly Review;Jun2009, Vol. 8 Issue 6, p47 

    The article provides updates on the developments within the pharmaceutical biotechnology industry. It notes that Phase III trials of Avastin, a drug intended to treat colon cancer from Genentech Inc., fails its primary endpoint. Dendreon has reported positive data from its Protect Phase III...

  • Long-Awaited Provenge Data Send Dendreon Soaring 133%. Morrison, Trista // BioWorld Today;4/15/2009, Vol. 20 Issue 71, p1 

    The article reports that the confirmatory Phase III clinical trial of prostate cancer vaccine Provenge of Dendreon Corp. has met its primary endpoint of improving overall survival that could pave the way for the first U.S. Food and Drug Administration's (FDA) approval of a therapeutic cancer...

  • Dendreon Enriches Coffers With $130M.  // Bioworld Week;10/22/2007, Vol. 15 Issue 43, p2 

    The article reports that Dendreon Corp. of Seattle, Washington plans to sell up to $130 million of its yet-to-be approved prostate cancer drug Provenge to Azimuth Opportunity Ltd. by April 2009 as it entered into an equity financing commitment in the U.S. If the firm chooses to use the facility...

  • Dendreon Enriches Coffers With $130M Financing.  // BioWorld Today;10/15/2007, Vol. 18 Issue 200, p2 

    The article reports that Dendreon Corp. has signed an equity financing commitment which will enable the biotechnology firm to sell its common stock to Azimuth Opportunity Ltd. over 18 months. Dendreon, the maker of Provenge, a prostate cancer drug, would sell up to $130 million worth of common...

  • Earnings Roundup. Powers, Marie // BioWorld Today;5/10/2013, Vol. 24 Issue 90, p8 

    The article reports on the net revenue of Seattle, Washington-based biopharmaceutical company Dendreon Corp. for the first quarter of 2013.

  • Corvas stockholders approve merger with Dendreon.  // PharmaWatch: Biotechnology;September 2003, Vol. 2 Issue 9, p17 

    Reports on the proposed merger between Corvas International and Dendreon Corp. Terms under the merger agreement; Benefits of the agreement for both parties; Significance of the agreement for the biotechnology industry.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics